Tinidazole

A nitroimidazole antimicrobial, FDA-approved for trichomoniasis, giardiasis, amebiasis and bacterial vaginosis.

psilodex.org/m/tinidazole · data v2026.10.05

Clinical contraindication: None listed; No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence: No psilocybin data
Half-life: 12–14 h; Approximate, in adults. Source under Interaction below.

Named in state rules?

Not namedColorado

Not namedOregon

PendingNew Mexico

Cite asPsilodex, “Tinidazole”, v2026.10.05. psilodex.org/m/tinidazole

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

FDA-approved for

Trichomoniasis
Giardiasis
Intestinal amebiasis and amebic liver abscess
Bacterial vaginosis (non-pregnant adult women)

Sources [1]

Other safety

Boxed warning: carcinogenicity seen in mice and rats given the related drug metronidazole long term; use is limited to labeled conditions.

About the medication itself, separate from any interaction with psilocybin.

Sources [1]

01 Interaction with psilocybin

No known interaction with psilocybin. Also, its label reports seizures and a reaction with alcohol up to 3 days after the last dose.

Detail Not studied with psilocybin, and no mechanism linking them has been described. Also, its label reports convulsive seizures and peripheral neuropathy (nerve damage in limbs). It also reports a disulfiram-like reaction (cramps, nausea, vomiting, headache, flushing) with alcohol during treatment and for 3 days afterward. Sources [1]

Human data with psilocybin: No psilocybin data; based on its label
Half-life: 12–14 h (FDA label, checked 2026-10-04)

Evidence types on this record

No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

1 listed · counted on reports

Lowers seizure threshold or carries seizure risk: Makes a seizure more likely, or has been linked to seizures. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-10-04

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

TINDAMAX (tinidazole) tablets (Mission Pharmacal) · FDA label (DailyMed) — revised 2021-12 | Lowers seizure threshold or carries seizure risk: 5.1 Neurological Adverse Reactions "Convulsive seizures and peripheral neuropathy, the latter characterized mainly by numbness or paresthesia of an extremity, have been reported in patients treated with tinidazole." | 7 Alcohols, Disulfiram (alcohol with tinidazole) "during tinidazole therapy and for 3 days afterward because abdominal cramps, nausea, vomiting, headaches, and flushing may occur." | 12.3 "The plasma half-life of tinidazole is approximately 12-14 hours."
Halman A, Kong G, Sarris J, Perkins D. Drug–drug interactions involving classic psychedelics: a systematic review. J Psychopharmacol 2024;38(1):3–18. — no reported interaction
Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976. — no reported interaction

Record history

v2026.10.02First published.
2026-10-04Last reviewed against its sources.

Report an error in this record →